Rafael’s Devimistat Faces Double Whammy of Failed Trials in Pancreatic Cancer and AML

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Rafael’s lead drug candidate has failed in a Phase III trial for pancreatic cancer and the company has been advised to stop a Phase III study of the product in AML.

Cancer-cells-pink-color_1200x675
• Source: Shutterstock

Rafael Pharmaceuticals, Inc.’s lead candidate, devimistat, has hit the buffers in two Phase III trials. It has missed the primary endpoint in a Phase III study for first-line metastatic pancreatic cancer, while a second Phase III trial in relapsed or refractory acute myeloid leukaemia (AML) has been stopped on the recommendation of its independent data monitoring committee due to efficacy concerns.

“We are disappointed by the results,” admitted Rafael Holdings CEO Ameet Mallik. Nonetheless, the company was keen to continue the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.